LS Investment Advisors LLC boosted its stake in shares of Laboratory Corporation of America Holdings (NYSE:LH) by 3.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,659 shares of the medical research company’s stock after buying an additional 175 shares during the period. LS Investment Advisors LLC’s holdings in Laboratory Corporation of America Holdings were worth $718,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. TNB Financial purchased a new stake in shares of Laboratory Corporation of America Holdings during the second quarter valued at approximately $208,000. Advisors Capital Management LLC increased its position in shares of Laboratory Corporation of America Holdings by 9.4% in the second quarter. Advisors Capital Management LLC now owns 28,494 shares of the medical research company’s stock valued at $4,392,000 after buying an additional 2,457 shares during the period. Baltimore Washington Financial Advisors Inc. increased its position in shares of Laboratory Corporation of America Holdings by 16.0% in the second quarter. Baltimore Washington Financial Advisors Inc. now owns 45,965 shares of the medical research company’s stock valued at $7,085,000 after buying an additional 6,335 shares during the period. Regent Investment Management LLC increased its position in shares of Laboratory Corporation of America Holdings by 226.1% in the second quarter. Regent Investment Management LLC now owns 5,769 shares of the medical research company’s stock valued at $889,000 after buying an additional 4,000 shares during the period. Finally, Winslow Evans & Crocker Inc. increased its position in shares of Laboratory Corporation of America Holdings by 0.6% in the second quarter. Winslow Evans & Crocker Inc. now owns 7,703 shares of the medical research company’s stock valued at $1,186,000 after buying an additional 49 shares during the period. Institutional investors own 91.64% of the company’s stock.

Laboratory Corporation of America Holdings (NYSE LH) traded down 0.42% during mid-day trading on Friday, reaching $153.91. The company had a trading volume of 460,530 shares. The firm has a market capitalization of $15.67 billion, a P/E ratio of 21.56 and a beta of 0.94. Laboratory Corporation of America Holdings has a one year low of $119.51 and a one year high of $164.22. The firm’s 50-day moving average is $155.89 and its 200-day moving average is $145.06.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.40 by $0.07. The business had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.36 earnings per share. On average, equities research analysts anticipate that Laboratory Corporation of America Holdings will post $9.50 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/19/ls-investment-advisors-llc-buys-175-shares-of-laboratory-corporation-of-america-holdings-lh-updated-updated-updated.html.

Several research analysts recently issued reports on the stock. Morgan Stanley upped their price target on shares of Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the stock an “overweight” rating in a research report on Thursday, August 10th. Barclays PLC upped their price target on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research report on Thursday, July 27th. Zacks Investment Research upgraded shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Craig Hallum reissued a “buy” rating and set a $179.00 price objective (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Finally, Credit Suisse Group cut Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 price objective for the company. in a report on Thursday, July 13th. They noted that the move was a valuation call. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Laboratory Corporation of America Holdings presently has an average rating of “Buy” and a consensus price target of $159.75.

In other news, CFO Glenn A. Eisenberg sold 5,968 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $159.46, for a total transaction of $951,657.28. Following the completion of the sale, the chief financial officer now owns 18,122 shares in the company, valued at $2,889,734.12. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Lance Berberian sold 3,613 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $139.84, for a total value of $505,241.92. Following the sale, the senior vice president now owns 5,789 shares of the company’s stock, valued at approximately $809,533.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,681 shares of company stock valued at $2,743,227. Corporate insiders own 0.90% of the company’s stock.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.